Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the
combination regimens gemcitabine–cisplatin and methotrexate–vinblastine–doxorubicin …

Despite recent advances in the identification of genomic alterations that lead to urothelial
oncogenesis in vitro, patients with advanced urothelial carcinomas continue to have poor …

Purpose: Urothelial carcinoma is a malignant cancer with frequent chromosomal
aberrations. Here, we investigated the application of a cost-effective, low-coverage whole …

Background While circulating tumor cells may serve as minimally invasive cancer markers
for bladder cancers, the relationship between primary bladder cancers and circulating tumor …

Serial evaluation of circulating tumor DNA may allow noninvasive assessment of drivers of
resistance to immune checkpoint inhibitors (ICIs) in advanced urothelial cancer (aUC). We …

Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need
of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum …

Background Urothelial carcinoma (UC) is the most common pathological type of bladder
cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC …

4 BIG QUESTIONS Page 1 P A UL BL O W 9 NOVEMBER 2017 | VOL 551 | NATURE | S51
BLADDER CANCER OUTLOOK 4 BIG QUESTIONS 1 3 2 4 QUESTION WHY IT MATTERS …

Opinion statement Despite significant advances and the approval of immune checkpoint
inhibitors, metastatic urothelial carcinoma (mUC) is still very hard to treat and has poor …

Urothelial carcinoma of the bladder (UCB) is one of the commonly diagnosed cancers in the
world. The UCB has the highest rate of recurrence of any malignancy. A genome-wide …